rad-140
ANABOLIC · NONSTEROIDAL SARM · ORAL · T½ 45–60 H
also: testolone · vosilasarm · EP0062
RAD140, now developed under the name vosilasarm, has a completed first-in-human phase 1 study in 22 postmenopausal women with metastatic breast cancer and is in phase 1/2 development. The trial defined a maximum tolerated dose but reported a high frequency of hepatic laboratory abnormalities, and the compound is not approved for any use.
// our evidence grade — unedited
A small first-in-human phase 1 oncology study defined a maximum tolerated dose but reported abnormal liver tests in roughly half of participants, and there is no human data of any kind outside advanced breast cancer.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | RAD140 (testolone, vosilasarm, EP0062) |
| cas | 1182367-47-0 |
| formula | C20H16ClN5O2 |
| molar mass | 393.8 g/mol |
| purity | ≥ 98% HPLC |
| form | research solution |
| storage | Reference material: store as a solid, desiccated and protected from light, at -20 °C for long-term stability; stock solutions typically stored at -80 °C with freeze-thaw cycles minimised. |
| solubility | Lipophilic small molecule; soluble in DMSO and ethanol, poorly soluble in aqueous buffer. Lot-specific figures should be taken from the certificate of analysis. |
// select size
crypto payment · research use only · not for human consumption
// others in Anabolic & Receptor